INVASC THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2006-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.invasc.net
INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria
Phase 2
Completed
- Conditions
- HypertensionDiabetes Mellitus, Type 2
- Interventions
- Drug: Active ControlDrug: INV-144
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- InVasc Therapeutics, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT01398423
Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome
- First Posted Date
- 2011-01-06
- Last Posted Date
- 2011-05-05
- Lead Sponsor
- InVasc Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT01271374
- Locations
- 🇺🇸
Atlanta Clinical Research Center, Tucker, Georgia, United States
Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension
- First Posted Date
- 2009-10-22
- Last Posted Date
- 2011-05-05
- Lead Sponsor
- InVasc Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00999752
- Locations
- 🇺🇸
Atlanta Vascular Research Foundation, Tucker, Georgia, United States
Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension
Not Applicable
Completed
- Conditions
- DiabetesHypertension
- Interventions
- Drug: accupril, placeboDrug: Quinapril (Accupril) plus Alpha Lipoic AcidDrug: accupril, alpha lipoic acid
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2011-05-05
- Lead Sponsor
- InVasc Therapeutics, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT00795262
- Locations
- 🇺🇸
Atlanta Vascular Research Foundation, Tucker, Georgia, United States
© Copyright 2025. All Rights Reserved by MedPath